Abstract:Peripheral blood leucocytes from 81 inclusion body myositis (IBM) patients and 45 healthy controls were analysed using flow cytometry. A supervised computational approach using the random forest classifier identified immune signatures in IBM, while unsupervised modelling stratified patients into distinct immunophenotypic clusters. These findings shed light on the underlying pathological mechanisms and hold potential for future clinical applications, spanning IBM diagnosis, prognosis and management. Objective Inclusion body myositis (IBM) is a progressive late‐onset muscle disease characterised by preferential weakness of quadriceps femoris and finger flexors, with elusive causes involving immune, degenerative, genetic and age‐related factors. Overlapping with normal muscle ageing makes diagnosis and prognosis problematic. Methods We characterised peripheral blood leucocytes in 81 IBM patients and 45 healthy controls using flow cytometry. Using a random forest classifier, we identified immune changes in IBM compared to HC. K‐means clustering and the random forest one‐versus‐rest model classified patients into three immunophenotypic clusters. Functional outcome measures including mTUG, 2MWT, IBM‐FRS, EAT‐10, knee extension and grip strength were assessed across clusters. Results The random forest model achieved a 94% AUC ROC with 82.76% specificity and 100% sensitivity. Significant differences were found in IBM patients, including increased CD8+ T‐bet+ cells, CD4+ T cells skewed towards a Th1 phenotype and altered γδ T cell repertoire with a reduced proportion of Vγ9+Vδ2+ cells. IBM patients formed three clusters: (i) activated and inflammatory CD8+ and CD4+ T‐cell profile and the highest proportion of anti‐cN1A‐positive patients in cluster 1; (ii) limited inflammation in cluster 2; (iii) highly differentiated, pro‐inflammatory T‐cell profile in cluster 3. Additionally, no significant differences in patients' age and gender were detected between immunophenotype clusters; however, worsening trends were detected with several functional outcomes. Conclusion These findings unveil distinct immune profiles in IBM, shedding light on underlying pathological mechanisms for potential immunoregulatory therapeutic development.

272nd ENMC International Workshop: 10 years of Progress - Revision of the ENMC 2013 Diagnostic Criteria for Inclusion Body Myositis and Clinical Trial Readiness. 16-18 June 2023, Hoofddorp, The Netherlands

275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9-11 February 2024, Hoofddorp, the Netherlands

214Th ENMC International Workshop: Establishing an International Consortium for Gene Discovery and Clinical Research for Congenital Muscle Disease, Heemskerk, the Netherlands, 6–18 October 2015

Ongoing developments in sporadic inclusion body myositis

271st ENMC international workshop: Towards a unifying effort to fight Kennedy's disease. 20-22 October 2023, Hoofddorp, Netherlands

Inclusion body myositis: an update

Exploration of New Contrasts, Targets, and MR Imaging and Spectroscopy Techniques for Neuromuscular Disease - A Workshop Report of Working Group 3 of the Biomedicine and Molecular Biosciences COST Action BM1304 MYO-MRI

Inclusion body myositis-health-related quality of life and care situation during phases of the "patience journey" in Germany: results from a qualitative study

E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021

Inclusion body myositis: Correcting mitochondfrial and lysosomal autophagy impairment as a potential therapeutic strategy

Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models

Quantitative muscle MRI in sporadic inclusion body myositis (sIBM): A prospective cohort study

A Cross-Sectional Study of Nemaline Myopathy

274th ENMC international workshop: recommendations for optimizing bone strength in neuromuscular disorders. Hoofddorp, The Netherlands, 19-21 January 2024

273rd ENMC International workshop: Clinico-Sero-morphological classification of the Antisynthetase syndrome. Amsterdam, The Netherlands, 27-29 October 2023

Volumetric muscle composition analysis in sporadic inclusion body myositis using fat‐referenced magnetic resonance imaging: Disease pattern, repeatability, and natural progression

Progress in muscle research through the international congress of neuromuscular diseases (ICNMD): a narrative review

New Approaches to Critical Illness Polyneuromyopathy: High-Resolution Neuromuscular Ultrasound Characteristics and Cytokine Profiling

Assessment of diagnostic criteria for multifocal motor neuropathy in patients included in the Italian database

Clinical and pathological characteristics of adult idiopathic inflammatory myopathies: A new understanding of diagnostic criteria and classification

MODERN ASPECTS OF ETIOPATHOGENESIS, DIAGNOSIS, CLINICAL COURSE AND TREATMENT OF SPORADIC INCLUSION BODY MYOSITIS